{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:17:35Z","timestamp":1770679055261,"version":"3.49.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T00:00:00Z","timestamp":1573689600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Circulating tumour DNA (ctDNA) has emerged as a promising blood-based biomarker for monitoring disease status of patients with advanced cancers. The presence of ctDNA in the blood is a result of biological processes, namely tumour cell apoptosis and\/or necrosis, and can be used to monitor different cancers by targeting cancer-specific mutation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We present the case of a 67\u2009year old Caucasian male that was initially treated with BRAF inhibitors followed by anti-CTLA4 and then anti-PD1 immunotherapy for metastatic melanoma but later developed colorectal cancer. The kinetics of ctDNA derived from each cancer type were monitored targeting <jats:italic>BRAF V600R<\/jats:italic> (melanoma) and <jats:italic>KRAS G13D<\/jats:italic> (colon cancer), specifically reflected the status of the patient\u2019s tumours. In fact, the discordant pattern of BRAF and KRAS ctDNA was significantly correlated with the clinical response of melanoma to pembrolizumab treatment and progression of colorectal cancer noted by PET and\/or CT scan. Based on these results, ctDNA can be used to specifically clarify disease status of patients with metachronous cancers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using cancer-specific mutational targets, we report here for the first time the efficacy of ctDNA to accurately provide a comprehensive outlook of the tumour status of two different cancers within one patient. Thus, ctDNA analysis has a potential clinical utility to delineate clinical information in patients with multiple cancer types.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-019-6336-3","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T16:02:49Z","timestamp":1573747369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report"],"prefix":"10.1186","volume":"19","author":[{"given":"Leslie","family":"Calapre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9417-1596","authenticated-orcid":false,"given":"Lydia","family":"Warburton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elin S.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"6336_CR1","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre L, et al. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 2017;404:62\u20139.","journal-title":"Cancer Lett"},{"issue":"4","key":"6336_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan JCM, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223\u201338.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6336_CR3","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1373\/clinchem.2014.222679","volume":"61","author":"E Heitzer","year":"2015","unstructured":"Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112\u201323.","journal-title":"Clin Chem"},{"issue":"2","key":"6336_CR4","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbcan.2016.03.006","volume":"1865","author":"JV Canzoniero","year":"2016","unstructured":"Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2016;1865(2):266\u201374.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"key":"6336_CR5","unstructured":"Bettegowda, C., et al., Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 2014. 6(224): p. 224ra24."},{"key":"6336_CR6","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/ncomms9760","volume":"6","author":"M Murtaza","year":"2015","unstructured":"Murtaza M, et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat Commun. 2015;6:8760.","journal-title":"Nat Commun"},{"key":"6336_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00009","volume":"1","author":"SQ Wong","year":"2017","unstructured":"Wong SQ, et al. Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma. JCO Precision Oncology. 2017;1:1\u201314.","journal-title":"JCO Precision Oncology"},{"issue":"5","key":"6336_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548\u201354.","journal-title":"Nat Med"},{"issue":"9","key":"6336_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","volume":"25","author":"L De Mattos-Arruda","year":"2014","unstructured":"De Mattos-Arruda L, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle. Ann Oncol. 2014;25(9):1729\u201335.","journal-title":"Ann Oncol"},{"issue":"5","key":"6336_CR10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1093\/annonc\/mdw037","volume":"27","author":"M Jamal-Hanjani","year":"2016","unstructured":"Jamal-Hanjani M, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862\u20137.","journal-title":"Ann Oncol"},{"key":"6336_CR11","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L De Mattos-Arruda","year":"2015","unstructured":"De Mattos-Arruda L, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.","journal-title":"Nat Commun"},{"issue":"13","key":"6336_CR12","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"S-J Dawson","year":"2013","unstructured":"Dawson S-J, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199\u2013209.","journal-title":"N Engl J Med"},{"key":"6336_CR13","doi-asserted-by":"crossref","unstructured":"Forshew, T., et al., Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Science translational medicine, 2012. 4(136): p. 136ra68-136ra68.","DOI":"10.1126\/scitranslmed.3003726"},{"issue":"8","key":"6336_CR14","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1093\/annonc\/mdv177","volume":"26","author":"J Tie","year":"2015","unstructured":"Tie J, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715\u201322.","journal-title":"Ann Oncol"},{"key":"6336_CR15","doi-asserted-by":"crossref","unstructured":"Garcia-Murillas, I., et al., Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science translational medicine, 2015. 7(302): p. 302ra133-302ra133.","DOI":"10.1126\/scitranslmed.aab0021"},{"issue":"7447","key":"6336_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","volume":"497","author":"M Murtaza","year":"2013","unstructured":"Murtaza M, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013;497(7447):108\u201312.","journal-title":"Nature"},{"issue":"1","key":"6336_CR17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/cam4.978","volume":"6","author":"W Wang","year":"2017","unstructured":"Wang W, Song Z, Zhang Y. A comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance. Cancer Med. 2017;6(1):154\u201362.","journal-title":"Cancer Med"},{"key":"6336_CR18","doi-asserted-by":"publisher","first-page":"20913","DOI":"10.1038\/srep20913","volume":"6","author":"D Zheng","year":"2016","unstructured":"Zheng D, et al. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance. Sci Rep. 2016;6:20913.","journal-title":"Sci Rep"},{"issue":"5","key":"6336_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/1078-0432.CCR-15-1031","volume":"22","author":"TK Sundaresan","year":"2016","unstructured":"Sundaresan TK, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. Clin Cancer Res. 2016;22(5):1103\u201310.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6336_CR20","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.molonc.2014.05.003","volume":"8","author":"BO Van Emburgh","year":"2014","unstructured":"Van Emburgh BO, et al. Acquired resistance to EGFR-targeted therapies in colorectal cancer. Mol Oncol. 2014;8(6):1084\u201394.","journal-title":"Mol Oncol"},{"issue":"39","key":"6336_CR21","doi-asserted-by":"publisher","first-page":"42008","DOI":"10.18632\/oncotarget.5788","volume":"6","author":"ES Gray","year":"2015","unstructured":"Gray ES, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6(39):42008\u201318.","journal-title":"Oncotarget"},{"issue":"1","key":"6336_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1373\/clinchem.2014.230235","volume":"61","author":"MF Sanmamed","year":"2015","unstructured":"Sanmamed MF, et al. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors. Clin Chem. 2015;61(1):297\u2013304.","journal-title":"Clin Chem"},{"issue":"3","key":"6336_CR23","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","volume":"6","author":"MR Girotti","year":"2016","unstructured":"Girotti MR, et al. Application of sequencing, liquid biopsies, and patient-derived Xenografts for personalized medicine in melanoma. Cancer Discov. 2016;6(3):286\u201399.","journal-title":"Cancer Discov"},{"issue":"6","key":"6336_CR24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/CMR.0000000000000187","volume":"25","author":"M Gonzalez-Cao","year":"2015","unstructured":"Gonzalez-Cao M, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res. 2015;25(6):486\u201395.","journal-title":"Melanoma Res"},{"key":"6336_CR25","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","volume":"14","author":"M Schreuer","year":"2016","unstructured":"Schreuer M, et al. Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors. J Transl Med. 2016;14:95.","journal-title":"J Transl Med"},{"key":"6336_CR26","doi-asserted-by":"crossref","unstructured":"Lee J, et al. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Ann Oncol. 2017;28.","DOI":"10.1093\/annonc\/mdx026"},{"key":"6336_CR27","doi-asserted-by":"crossref","unstructured":"Reid AL, et al. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clin Biochem. 2015;48.","DOI":"10.1016\/j.clinbiochem.2014.12.007"},{"key":"6336_CR28","doi-asserted-by":"crossref","unstructured":"Calapre L, et al. Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Mol Oncol. 2018.","DOI":"10.1002\/1878-0261.12391"},{"key":"6336_CR29","doi-asserted-by":"crossref","unstructured":"Bettegowda C, et al. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6.","DOI":"10.1158\/1538-7445.AM2014-5606"},{"key":"6336_CR30","doi-asserted-by":"crossref","unstructured":"Tie, J., et al., Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med, 2016. 8(346): p. 346ra92.","DOI":"10.1126\/scitranslmed.aaf6219"},{"key":"6336_CR31","doi-asserted-by":"crossref","unstructured":"Le, D.T., et al., KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. Journal of Clinical Oncology, 2018. 36(15_suppl): p. 3514\u20133514.","DOI":"10.1200\/JCO.2018.36.15_suppl.3514"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-6336-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-6336-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:07:50Z","timestamp":1605226070000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-6336-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["6336"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-6336-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]},"assertion":[{"value":"17 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from patients under approved Human Research Ethics Committee protocols from Edith Cowan University (No. 2932) and Sir Charles Gairdner Hospital (No.2007\u2013123). De-identification of images was performed and written consent for publication attained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1109"}}